Chapter/Section Purchase

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Duchenne Muscular Dystrophy Drugs
1.2 Key Market Segments
1.2.1 Duchenne Muscular Dystrophy Drugs Segment by Type
1.2.2 Duchenne Muscular Dystrophy Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Duchenne Muscular Dystrophy Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Duchenne Muscular Dystrophy Drugs Market Competitive Landscape
3.1 Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Duchenne Muscular Dystrophy Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Duchenne Muscular Dystrophy Drugs Sales Sites, Area Served, Product Type
3.6 Duchenne Muscular Dystrophy Drugs Market Competitive Situation and Trends
3.6.1 Duchenne Muscular Dystrophy Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Duchenne Muscular Dystrophy Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Duchenne Muscular Dystrophy Drugs Industry Chain Analysis
4.1 Duchenne Muscular Dystrophy Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Duchenne Muscular Dystrophy Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Duchenne Muscular Dystrophy Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2019-2024)
6.3 Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Duchenne Muscular Dystrophy Drugs Price by Type (2019-2024)
7 Duchenne Muscular Dystrophy Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Duchenne Muscular Dystrophy Drugs Market Sales by Application (2019-2024)
7.3 Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Duchenne Muscular Dystrophy Drugs Sales Growth Rate by Application (2019-2024)
8 Duchenne Muscular Dystrophy Drugs Market Segmentation by Region
8.1 Global Duchenne Muscular Dystrophy Drugs Sales by Region
8.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Region
8.1.2 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Duchenne Muscular Dystrophy Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Duchenne Muscular Dystrophy Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Biogen
9.1.1 Biogen Duchenne Muscular Dystrophy Drugs Basic Information
9.1.2 Biogen Duchenne Muscular Dystrophy Drugs Product Overview
9.1.3 Biogen Duchenne Muscular Dystrophy Drugs Product Market Performance
9.1.4 Biogen Business Overview
9.1.5 Biogen Duchenne Muscular Dystrophy Drugs SWOT Analysis
9.1.6 Biogen Recent Developments
9.2 Roche
9.2.1 Roche Duchenne Muscular Dystrophy Drugs Basic Information
9.2.2 Roche Duchenne Muscular Dystrophy Drugs Product Overview
9.2.3 Roche Duchenne Muscular Dystrophy Drugs Product Market Performance
9.2.4 Roche Business Overview
9.2.5 Roche Duchenne Muscular Dystrophy Drugs SWOT Analysis
9.2.6 Roche Recent Developments
9.3 Daiichi Sankyo
9.3.1 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Basic Information
9.3.2 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Overview
9.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Market Performance
9.3.4 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs SWOT Analysis
9.3.5 Daiichi Sankyo Business Overview
9.3.6 Daiichi Sankyo Recent Developments
9.4 Pfizer
9.4.1 Pfizer Duchenne Muscular Dystrophy Drugs Basic Information
9.4.2 Pfizer Duchenne Muscular Dystrophy Drugs Product Overview
9.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Recent Developments
9.5 Cumberland Pharmaceuticals
9.5.1 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Basic Information
9.5.2 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Overview
9.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Market Performance
9.5.4 Cumberland Pharmaceuticals Business Overview
9.5.5 Cumberland Pharmaceuticals Recent Developments
9.6 Santhera Pharmaceuticals
9.6.1 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Basic Information
9.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Overview
9.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Market Performance
9.6.4 Santhera Pharmaceuticals Business Overview
9.6.5 Santhera Pharmaceuticals Recent Developments
9.7 Taiho Pharmaceutical
9.7.1 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Basic Information
9.7.2 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Overview
9.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Market Performance
9.7.4 Taiho Pharmaceutical Business Overview
9.7.5 Taiho Pharmaceutical Recent Developments
9.8 Teijin Pharma
9.8.1 Teijin Pharma Duchenne Muscular Dystrophy Drugs Basic Information
9.8.2 Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Overview
9.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Market Performance
9.8.4 Teijin Pharma Business Overview
9.8.5 Teijin Pharma Recent Developments
9.9 Akashi Therapeutics
9.9.1 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Basic Information
9.9.2 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Overview
9.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Market Performance
9.9.4 Akashi Therapeutics Business Overview
9.9.5 Akashi Therapeutics Recent Developments
9.10 Sarepta Therapeutics
9.10.1 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Basic Information
9.10.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Overview
9.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Market Performance
9.10.4 Sarepta Therapeutics Business Overview
9.10.5 Sarepta Therapeutics Recent Developments
9.11 BioMarin
9.11.1 BioMarin Duchenne Muscular Dystrophy Drugs Basic Information
9.11.2 BioMarin Duchenne Muscular Dystrophy Drugs Product Overview
9.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Product Market Performance
9.11.4 BioMarin Business Overview
9.11.5 BioMarin Recent Developments
9.12 Fibrogen Inc
9.12.1 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Basic Information
9.12.2 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Overview
9.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Market Performance
9.12.4 Fibrogen Inc Business Overview
9.12.5 Fibrogen Inc Recent Developments
9.13 Nobelpharma Co. Ltd
9.13.1 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Basic Information
9.13.2 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Overview
9.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Market Performance
9.13.4 Nobelpharma Co. Ltd Business Overview
9.13.5 Nobelpharma Co. Ltd Recent Developments
9.14 Eloxx Pharmaceuticals
9.14.1 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Basic Information
9.14.2 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Overview
9.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Market Performance
9.14.4 Eloxx Pharmaceuticals Business Overview
9.14.5 Eloxx Pharmaceuticals Recent Developments
10 Duchenne Muscular Dystrophy Drugs Market Forecast by Region
10.1 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast
10.2 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region
10.2.4 South America Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Duchenne Muscular Dystrophy Drugs by Type (2025-2030)
11.1.2 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Duchenne Muscular Dystrophy Drugs by Type (2025-2030)
11.2 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Duchenne Muscular Dystrophy Drugs Sales (K Units) Forecast by Application
11.2.2 Global Duchenne Muscular Dystrophy Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings